Trial Profile
A 12-week, Multicenter, Randomized, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster 100/6mg NEXThaler, 2 Inhalations b.i.d, Versus Foster 100/6mg pMDI, 2 Puffs b.i.d in Patients With Controlled Asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jul 2023
Price :
$35
*
At a glance
- Drugs Beclometasone/formoterol (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms FORTUNE
- Sponsors Chiesi Farmaceutici
- 24 May 2023 Primary endpoint has been met. (Demonstration of non-inferiority of Foster 100/6mg NEXThaler versus Foster 100/6mg pMDI in terms of pulmonary function), as per results presented at the 119th International Conference of the American Thoracic Society.
- 24 May 2023 Results presented at the 119th International Conference of the American Thoracic Society
- 08 Jul 2022 Status changed from recruiting to completed.